A SYSTEMATIC REVIEW OF THE HEALTH-RELATED QUALITY OF LIFE AND COSTS IN DIFFUSE LARGE B-CELL LYMPHOMA
Author(s)
Chadda S1, Nelson L1, Podlogar S2, Garside J3, Upton CM1
1SIRIUS Market Access, London, UK, 2Janssen Global Oncology, Raritan, NJ, USA, 3Janssen, High Wycombe, UK
OBJECTIVES: As survival outcomes improve for patients with diffuse large B-cell lymphoma (DLBCL), it is increasingly important to understand costs and humanistic burden to evaluate the need for new treatments. We conducted systematic reviews to understand the health-related quality of life (HRQoL) of patients with DLBCL and costs associated with treatment. METHODS: MEDLINE, EMBASE, EconLit, UK National Health Service Economic Evaluation Database, and Tufts University Cost-Effectiveness Analysis Registry were searched for studies published between 2000-2016. Trial registries and health technology assessment websites were searched for appraisals with relevant economic and HRQoL data; abstracts were identified from ASCO, ESMO, ASH, EHA, and ISPOR. RESULTS: After screening, 25 of 2184 references were included for HRQoL; 20 of 1481 references were included for costs. Ten studies used the EORTC QLQ-C30. The EQ-5D and FACT-Lym are used in trials with unpublished data. Patients who achieve complete response after first-line treatment have significantly greater improvements on HRQoL compared to non-complete responders (p=0.05). Symptoms that compromise HRQoL persist for up to 5 years for patients that do not respond to first-line treatment CONCLUSIONS: Novel, targeted DLBCL first-line treatments have the potential to provide a more cost-effective, manageably budgeted treatment paradigm, reduce disease progression, and improve HRQoL. Although DLBCL subgroups are recognized in clinical guidelines, further studies are needed to understand their specific HRQoL and economic burden.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PCN104
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Oncology, Systemic Disorders/Conditions